Every material Form 8-K Artiva Biotherapeutics, Inc. has filed with the SEC since August 06, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Artiva Biotherapeutics will stop developing its lead candidate AlloNK after updated data showed durability of clinical response did not meet its required threshold, and two Grade 5 safety events occurred in its trials. The company is reducing its workforce by about 94% and exploring strategic alternatives, including a merger, sale or licensing of assets, or dissolution and liquidation, which could affect the value returned to shareholders.
Preliminary cash, cash equivalents and investments were about $319.1 million as of September 30, 2026 (unaudited)
Workforce reduction of about 94% expected to be completed in the first quarter of 2027; a significant majority of Wind Down costs expected in Q4 2026
Total Wind Down costs cannot be reasonably estimated at this time
Leerink Partners engaged as financial advisor; planned Phase 3 trial will not be initiated
At its September 8, 2026 annual meeting, Artiva Biotherapeutics stockholders approved an amendment to the 2024 Equity Incentive Plan that adds 5,097,095 shares for issuance and counts shares issuable under pre-funded warrants in the annual automatic share reserve increase. Stockholders also re-elected two Class II directors and ratified KPMG LLP as the auditor for fiscal 2026, so shareholders face potential dilution from the expanded share reserve.
Plan amendment adds 5,097,095 shares of common stock for issuance; the board approved it on July 15, 2026
Brian Daniels, M.D. and Laura Stoppel, Ph.D. elected as Class II directors with terms through the 2029 annual meeting
Proposal 3 approved with 32,527,133 votes for and 6,816,989 against
KPMG LLP ratified as independent registered public accounting firm for fiscal year ending December 31, 2026
Artiva Biotherapeutics reported a second-quarter 2026 net loss of $25.0 million, up from $21.3 million a year earlier, as research and development expenses rose to $21.9 million from $17.9 million. The company said cash, cash equivalents and investments of $349.4 million are expected to fund operations into 2029, and it plans to start a Phase 3 trial of AlloNK in refractory rheumatoid arthritis in the second half of 2026.
Net loss of $25.0 million for the quarter ended June 30, 2026, versus $21.3 million for the same quarter of 2025
Research and development expenses of $21.9 million, compared with $17.9 million a year earlier
Cash, cash equivalents and investments of $349.4 million as of June 30, 2026, expected to fund operations into 2029
Phase 3 randomized trial of AlloNK plus rituximab in about 150 refractory RA patients to begin in the second half of 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Artiva Biotherapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →